Ascendis Pharma A/S (ASND) Stock Price

Ascendis Pharma A/S Price

NASDAQ·CLOSED
218.24EUR+2.47 (+1.14 %)
Market closed

Over the last 13 years Ascendis Pharma A/S grew revenue by 33.9% annually, reaching 800.43 M EUR. For Ascendis Pharma A/S, the net margin of -31.7% is up versus -4,931.6% a few years ago. The consensus 12-month price target for Ascendis Pharma A/S is 225.13 EUR, about 3.2% above where the stock trades today. Of 24 analysts, 23 rate the stock a buy — an overall Buy consensus. The stock trades about 15% above its 52-week low.

Ascendis Pharma A/S stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Ascendis Pharma A/S over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Ascendis Pharma A/S stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Ascendis Pharma A/S's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Ascendis Pharma A/S Stock Price History
DateAscendis Pharma A/S Price
8/19/2026218.24 EUR
8/18/2026215.77 EUR
8/14/2026215.49 EUR
8/13/2026213.49 EUR
8/12/2026222.03 EUR
8/10/2026219.56 EUR
8/7/2026221.52 EUR
8/6/2026216.78 EUR
8/5/2026211.88 EUR
8/4/2026212.22 EUR
8/3/2026211.23 EUR
7/31/2026211.63 EUR
7/30/2026217.84 EUR
7/29/2026218.69 EUR
7/28/2026220.77 EUR
7/27/2026219.88 EUR
7/24/2026220.26 EUR
7/23/2026219.22 EUR
7/22/2026218.59 EUR
7/21/2026221.42 EUR
7/20/2026251.76 EUR
7/17/2026266.01 EUR
7/15/2026268.57 EUR
6/29/2026263.70 EUR
6/26/2026260.75 EUR
6/12/2026218.06 EUR
6/11/2026215.60 EUR
6/10/2026209.79 EUR
6/5/2026210.45 EUR
6/4/2026218.84 EUR
6/3/2026216.79 EUR
6/2/2026216.60 EUR
6/1/2026218.82 EUR
5/29/2026224.11 EUR
5/28/2026237.47 EUR
5/27/2026235.26 EUR
5/26/2026239.65 EUR
5/22/2026247.05 EUR
5/21/2026247.51 EUR
5/20/2026241.34 EUR
5/19/2026237.98 EUR
5/14/2026206.82 EUR
4/22/2026231.05 EUR
4/21/2026240.29 EUR
4/20/2026245.38 EUR
4/16/2026242.95 EUR
4/15/2026241.71 EUR
4/14/2026249.84 EUR
4/13/2026248.55 EUR
4/9/2026241.71 EUR
4/8/2026233.20 EUR
4/7/2026220.48 EUR
4/6/2026226.69 EUR
4/2/2026229.25 EUR
4/1/2026228.24 EUR
3/31/2026228.73 EUR
3/30/2026218.35 EUR
3/27/2026216.95 EUR
3/26/2026220.60 EUR
3/25/2026220.90 EUR
3/24/2026215.54 EUR
3/23/2026218.06 EUR
3/20/2026221.88 EUR
3/19/2026223.82 EUR
3/18/2026227.41 EUR
3/17/2026228.06 EUR
3/16/2026231.03 EUR
3/13/2026225.98 EUR
3/12/2026229.01 EUR
3/11/2026227.50 EUR
3/10/2026240.52 EUR
3/9/2026239.92 EUR
3/6/2026240.65 EUR
3/5/2026237.35 EUR
3/4/2026241.38 EUR
3/3/2026239.22 EUR
3/2/2026242.09 EUR
2/27/2026233.50 EUR
2/26/2026228.99 EUR
2/25/2026228.00 EUR
2/24/2026234.99 EUR
2/23/2026234.95 EUR
2/20/2026225.00 EUR
2/19/2026230.21 EUR
2/18/2026226.83 EUR
2/17/2026223.41 EUR
2/13/2026216.32 EUR
2/12/2026218.10 EUR
2/11/2026221.49 EUR
2/10/2026224.19 EUR
2/9/2026222.03 EUR
2/6/2026222.15 EUR
2/5/2026217.38 EUR
2/4/2026219.73 EUR
2/3/2026224.67 EUR
2/2/2026223.59 EUR
1/30/2026226.10 EUR
1/29/2026223.95 EUR
1/28/2026222.45 EUR
1/27/2026238.80 EUR
1/26/2026233.65 EUR
1/23/2026235.39 EUR
1/22/2026228.65 EUR
1/21/2026216.66 EUR
1/20/2026215.58 EUR
1/16/2026205.83 EUR
1/15/2026215.04 EUR
1/14/2026217.32 EUR
1/13/2026215.05 EUR
1/12/2026208.76 EUR
1/9/2026202.99 EUR
1/8/2026208.75 EUR
1/7/2026213.28 EUR
1/6/2026209.29 EUR
1/5/2026213.15 EUR
1/2/2026213.29 EUR
12/31/2025213.24 EUR
12/30/2025209.34 EUR
12/29/2025211.02 EUR
12/26/2025208.98 EUR
12/24/2025212.81 EUR
12/23/2025209.23 EUR
12/22/2025209.43 EUR
12/19/2025199.99 EUR
12/18/2025199.80 EUR
12/17/2025202.82 EUR
12/16/2025212.11 EUR
12/15/2025213.24 EUR
12/12/2025220.42 EUR
12/11/2025210.16 EUR
12/10/2025201.24 EUR
12/9/2025196.63 EUR
12/8/2025207.12 EUR
12/5/2025205.44 EUR
12/4/2025208.58 EUR
12/3/2025200.50 EUR
12/2/2025202.16 EUR
12/1/2025210.85 EUR
11/28/2025212.33 EUR
11/26/2025210.01 EUR
11/25/2025206.65 EUR
11/24/2025209.03 EUR
11/21/2025210.49 EUR
11/20/2025209.55 EUR
11/19/2025212.15 EUR
11/18/2025217.13 EUR
11/17/2025216.56 EUR
11/14/2025204.40 EUR
11/13/2025206.45 EUR
11/12/2025199.22 EUR
11/11/2025201.16 EUR
11/10/2025196.01 EUR
11/7/2025197.74 EUR
11/6/2025199.28 EUR
11/5/2025197.75 EUR
11/4/2025208.24 EUR
11/3/2025200.98 EUR
10/31/2025201.60 EUR
10/30/2025203.71 EUR
10/29/2025205.71 EUR
10/28/2025205.91 EUR
10/27/2025203.23 EUR
10/23/2025201.01 EUR
10/22/2025202.70 EUR
10/21/2025200.59 EUR
10/20/2025205.21 EUR
10/16/2025207.03 EUR
10/15/2025207.12 EUR
10/14/2025208.71 EUR
10/13/2025208.43 EUR
10/9/2025214.77 EUR
10/8/2025210.13 EUR
10/7/2025209.86 EUR
10/6/2025210.83 EUR
10/2/2025200.97 EUR
10/1/2025204.11 EUR
9/30/2025198.81 EUR
9/29/2025191.60 EUR
9/25/2025189.74 EUR
9/24/2025193.28 EUR
9/23/2025193.98 EUR
9/22/2025196.42 EUR
9/18/2025199.37 EUR
9/17/2025199.59 EUR
9/16/2025197.24 EUR
9/15/2025194.62 EUR
9/11/2025197.67 EUR
9/10/2025198.46 EUR
9/9/2025202.91 EUR
9/8/2025205.22 EUR
9/4/2025198.13 EUR
9/3/2025200.02 EUR
9/2/2025199.16 EUR
8/28/2025193.90 EUR
8/27/2025193.01 EUR
8/26/2025196.66 EUR
8/25/2025190.37 EUR
8/21/2025192.80 EUR
Access this data via the Eulerpool API
Get Free API Key

Ascendis Pharma A/S Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
308.64 M EUR
-517.19 M EUR
-557.12 M EUR
Jan 1, 2024
420.80 M EUR
-356.11 M EUR
-437.51 M EUR
Jan 1, 2025
800.43 M EUR
-184.43 M EUR
-253.46 M EUR
Jan 1, 2026 (e)
1.57 B EUR
-1.08 B EUR
614.64 M EUR
Jan 1, 2027 (e)
2.32 B EUR
-1.57 B EUR
532.43 M EUR
Jan 1, 2028 (e)
2.49 B EUR
-2.01 B EUR
946.04 M EUR
Jan 1, 2029 (e)
2.99 B EUR
-2.41 B EUR
1.11 B EUR
Jan 1, 2030 (e)
3.34 B EUR
-2.69 B EUR
1.26 B EUR

Ascendis Pharma A/S Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 21, 2026, 7:24 AM
 
REVENUEB EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB EUR
EBITB EUR
EBIT MARGIN%
NET INCOMEB EUR
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.010.01–0.010.020.010.010.060.310.420.801.572.322.492.993.34
-43.75-44.44-80.001,100.0025.00-46.6712.50555.56422.0336.3690.4896.7547.337.5519.9711.73
100.00100.00100.00100.00100.00100.0044.4476.2783.4487.8685.1385.1385.1385.1385.1385.13
0.010.01–0.010.020.01–0.050.260.370.681.341.972.122.552.85
-0.05-0.08-0.13-0.18-0.26-0.48-0.52-0.63-0.52-0.36-0.18-1.08-1.57-2.01-2.41-2.69
-533.33-1,680.00-12,900.00-1,491.67-1,746.67-6,025.00-5,800.00-1,071.19-167.86-84.76-23.00-68.81-67.79-80.59-80.58-80.59
-0.04-0.08-0.14-0.15-0.25-0.48-0.44-0.67-0.56-0.44-0.250.610.530.951.111.26
245.45107.8981.014.9068.0092.06-8.4752.14-17.36-21.54-42.11-342.69-13.3677.8217.0214.00
25.1332.4338.7043.3747.9953.7653.8555.9956.6159.7961.3861.3861.3861.3861.3861.38
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Ascendis Pharma A/S generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Ascendis Pharma A/S retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Ascendis Pharma A/S's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Ascendis Pharma A/S has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Ascendis Pharma A/S's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Ascendis Pharma A/S stock margins

The Ascendis Pharma A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ascendis Pharma A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ascendis Pharma A/S.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
54.71 %
-5,808.59 %
-4,931.56 %
Jan 1, 2022
76.28 %
-1,068.30 %
-1,139.63 %
Jan 1, 2023
83.36 %
-167.57 %
-180.51 %
Jan 1, 2024
87.83 %
-84.63 %
-103.97 %
Jan 1, 2025
85.08 %
-23.04 %
-31.67 %
Jan 1, 2026 (e)
85.08 %
-68.83 %
39.04 %
Jan 1, 2027 (e)
85.08 %
-67.81 %
22.95 %
Jan 1, 2028 (e)
85.08 %
-80.59 %
37.92 %

Ascendis Pharma A/S Stock Revenue, EBIT, Earnings per Share

The Ascendis Pharma A/S earnings per share therefore indicates how much revenue Ascendis Pharma A/S has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.17 EUR
-9.71 EUR
-8.24 EUR
Jan 1, 2022
1.06 EUR
-11.30 EUR
-12.05 EUR
Jan 1, 2023
5.45 EUR
-9.14 EUR
-9.84 EUR
Jan 1, 2024
7.04 EUR
-5.96 EUR
-7.32 EUR
Jan 1, 2025
13.04 EUR
-3.00 EUR
-4.13 EUR
Jan 1, 2026 (e)
25.40 EUR
-17.65 EUR
9.92 EUR
Jan 1, 2027 (e)
37.42 EUR
-25.62 EUR
8.59 EUR
Jan 1, 2028 (e)
40.25 EUR
-32.76 EUR
15.26 EUR

Ascendis Pharma A/S business model & stock analysis

Ascendis Pharma A/S is a biopharmaceutical company based in Denmark that focuses on developing innovative therapies for diseases that currently have no suitable treatment options. The company was founded in 2007 and is headquartered in Hellerup, Denmark. History The company was founded by an experienced team of researchers and professionals from the pharmaceutical and biotech industry who recognized the need for new therapies for chronic diseases. They used innovative technologies to develop drugs that would have longer-lasting effects, thus reducing the need for frequent doses. In 2015, the company went public to raise additional capital for the further development of their technologies and products. Business model Ascendis Pharma A/S is working on the development of drugs using a proprietary technology platform called TransCon technology. TransCon technology is a novel delivery system that allows drugs to remain in the body for longer periods of time, thus achieving a continuous effect. This leads to a reduced need for frequent doses, improving patient care and adherence to therapy. The company follows an asset-based business model strategy. It aims to market its products globally through a licensing and partnering approach. By partnering with established pharmaceutical companies, Ascendis Pharma A/S can introduce their drugs into broader markets while ensuring resources for further research and development. Divisions Ascendis Pharma A/S has two main business divisions: 1. Endocrinology: Ascendis Pharma A/S is a leader in the development of therapies for diseases caused by hormonal disorders. The TransCon technology is used for the delivery of hormones such as growth hormone, parathyroid hormone, follicle-stimulating hormone, and luteinizing hormone to achieve continuous release in the body. 2. Oncology: The company also utilizes the TransCon technology for the delivery of cytokines for cancer immunotherapy. Products The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone, a growth hormone therapy that has longer-lasting effects and only needs to be administered once a week for children with growth hormone deficiency. The company also has TransCon PTH and TransCon CNP in the endocrinology pipeline. In oncology, the company has developed TransCon IL-2, an interleukin-2 immunotherapy for cancer. Summary Ascendis Pharma A/S is an innovative biopharmaceutical company specializing in the development of therapies for chronic diseases. The company utilizes its proprietary technology platform, TransCon technology, to develop drugs that have longer-lasting effects and reduce the need for frequent doses. It focuses on endocrinology and oncology and follows an asset-based business model strategy by entering partnerships with established pharmaceutical companies. The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone.

Ascendis Pharma A/S SWOT Analysis

Strengths

Ascendis Pharma A/S boasts a strong and innovative product portfolio, which includes several potential breakthrough treatments in the biopharmaceutical industry. The company's focus on developing novel therapies for rare diseases positions them as a leading player in this niche market segment.

Ascendis Pharma A/S has established strategic partnerships and collaborations with prominent pharmaceutical companies and research institutions. These alliances provide access to additional resources, expertise, and funding, enhancing the company's research and development capabilities.

Weaknesses

The company's success heavily relies on the performance and approval of its key products in the pipeline. Any setbacks or delays in their development or regulatory processes could significantly impact Ascendis Pharma A/S's financial stability and growth prospects.

As a biopharmaceutical company operating in a highly regulated industry, Ascendis Pharma A/S faces inherent risks associated with compliance, clinical trials, and regulatory approvals. Any failure to meet regulatory requirements or unexpected safety concerns may hinder product development and market access.

Opportunities

The increasing prevalence and awareness of rare diseases present a significant opportunity for Ascendis Pharma A/S. The company's focus on developing targeted therapies for such conditions allows them to tap into an underserved market and potentially achieve substantial market share.

Ascendis Pharma A/S has the potential to expand its presence in international markets. By leveraging strategic partnerships and collaborations, the company can explore new geographic regions, access diverse patient populations, and capitalize on the global demand for innovative treatments.

Threats

Ascendis Pharma A/S faces significant competition from established pharmaceutical companies in the rare disease space. These competitors may have greater financial resources, established market presence, and a wider range of product offerings, posing a challenge to Ascendis Pharma A/S's market position.

The biopharmaceutical industry is subject to economic and market fluctuations. Economic downturns, changes in healthcare policies, or shifts in consumer buying patterns can impact Ascendis Pharma A/S's revenue streams and hinder its growth potential.

Ascendis Pharma A/S Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Ascendis Pharma A/S Employees
Details
Date
Ascendis Pharma A/S Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Ascendis Pharma A/S Segments

Ascendis Pharma A/S Revenue by Region

  • 3 Years

  • Max

United States
North America
Europe [member]
Rest of world [member]
DENMARK
CHINA
Details
Date
United States
North America
Europe [member]
Rest of world [member]
DENMARK
CHINA
Jan 1, 2021
0.00 EUR
6.86 M EUR
0.00 EUR
0.00 EUR
0.00 EUR
922,000.00 EUR
Jan 1, 2024
0.00 EUR
233.22 M EUR
123.34 M EUR
7.09 M EUR
95.40 M EUR
0.00 EUR
Jan 1, 2025
546.39 M EUR
0.00 EUR
120.95 M EUR
52.80 M EUR
12.90 M EUR
0.00 EUR

Ascendis Pharma A/S Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Ascendis Pharma A/S historical P/E ratio, EBIT multiple, and P/S ratio

Ascendis Pharma A/S annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Ascendis Pharma A/S shares outstanding

The number of shares of Ascendis Pharma A/S was 61.38 M in 2025. This indicates how many shares Ascendis Pharma A/S is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
53.85 M Stocks
Jan 1, 2022
55.99 M Stocks
Jan 1, 2023
56.61 M Stocks
Jan 1, 2024
59.79 M Stocks
Jan 1, 2025
61.38 M Stocks
Jan 1, 2026 (e)
61.38 M Stocks
Jan 1, 2027 (e)
61.38 M Stocks
Jan 1, 2028 (e)
61.38 M Stocks

Current Ascendis Pharma A/S forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.59 %
Buy
95.83 % (23)
Hold
4.17 % (1)
Sell
0.00 % (0)
12M Price Target
225.13
Last Price
218.24
Currency
EUR
12M Return Potential
3.16 %
LTM Return
0 %

Ascendis Pharma A/S Analyst Rating Actions

DateFirmActionRatingReliability
8/14/2026
TD Cowen
TD Cowen
MaintainedBuy60
8/14/2026
RBC Capital
RBC Capital
MaintainedOutperform48
8/14/2026
Barclays
Barclays
MaintainedOverweight55
7/23/2026
Morgan Stanley
Morgan Stanley
MaintainedOverweight49
7/7/2026
RBC Capital
RBC Capital
MaintainedOutperform48
5/15/2026
Evercore ISI Group
Evercore ISI Group
MaintainedOutperform62
5/11/2026
Barclays
Barclays
MaintainedOverweight55
5/8/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
4/16/2026
B of A Securities
B of A Securities
MaintainedBuy68
4/9/2026
Wedbush
Wedbush
MaintainedOutperform55

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Ascendis Pharma A/S Earnings Calls

Ascendis Pharma A/S Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/5/20261.40EUR-338.19 MEUR-2026 Q2
4/29/20260.30EUR-279.93 MEUR-2026 Q1
2/10/2026-0.04EUR-251.23 MEUR-2025 Q4
4/25/2024-2.27EUR-70.36 MEUR-2024 Q1
2/14/2024-2.48EUR-61.60 MEUR-2023 Q4
8/8/2023-2.79EUR-23.78 MEUR-2023 Q2
5/9/2023-2.71EUR-19.51 MEUR-2023 Q1
2/28/2023-2.73EUR-20.69 MEUR-2022 Q4
11/2/2022-2.54EUR-9.02 MEUR-2022 Q3
8/10/2022-2.18EUR-5.90 MEUR-2022 Q2

EESG©

Eulerpool ESG Scorecard© for the Ascendis Pharma A/S stock

57/100
35
Environment
99
Social
36
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Ascendis Pharma A/S shareholder structure

% Name
16.58841%
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
8.16796%
AVORO CAPITAL ADVISORS LLC
AVORO CAPITAL ADVISORS LLC
7.76612%
WESTFIELD CAPITAL MANAGEMENT CO LP
WESTFIELD CAPITAL MANAGEMENT CO LP
6.25460%
FMR LLC
FMR LLC
5.21166%
ARTISAN PARTNERS LIMITED PARTNERSHIP
ARTISAN PARTNERS LIMITED PARTNERSHIP
3.31066%
FRANKLIN RESOURCES INC
FRANKLIN RESOURCES INC
...

Ascendis Pharma A/S Beneficial Ownership Filings (SEC 13D/G)

Free Float
99.1%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
13.90%
Artisan Partners Limited Partnership
Artisan Partners Limited Partnership
SEC ↗
13.90%
Artisan Investments GP LLC
Artisan Investments GP LLC
SEC ↗
13.30%
RA Capital Management, L.P.
RA Capital Management, L.P.
SEC ↗
11.00%
Oleg Nodelman
Oleg Nodelman
SEC ↗
11.00%
EcoR1 Capital, LLC
EcoR1 Capital, LLC
SEC ↗
10.90%
Rajeev Shah
Rajeev Shah
SEC ↗
10.90%
Peter Kolchinsky
Peter Kolchinsky
SEC ↗
10.10%
2.
2.
SEC ↗
9.90%
T. Rowe Price Investment Management, Inc.
T. Rowe Price Investment Management, Inc.
SEC ↗
8.48%
Westfield Capital Management Company, L.P.
Westfield Capital Management Company, L.P.
SEC ↗

Ascendis Pharma A/S Executives and Management Board

15 members · avg. age 54 · 33 % women

Management

JM

Mr. Jan Moller Mikkelsen (65)

President, Chief Executive Officer, Executive Director, Member of the Executive Board · since 2007

–
SS

Mr. Scott Smith (51)

Chief Financial Officer, Executive Vice President, Member of the Executive Board

–
LS

Ms. Lotte Soenderbjerg (63)

Executive Vice President, Chief Administrative Officer, Member of the Executive Board

–
MJ

Mr. Michael Jensen (53)

Executive Vice President, Chief Legal Officer, Member of the Executive Board · since 2008

–
FJ

Mr. Flemming Jensen (64)

Executive Vice President, Product Supply and Quality

–
AS

Dr. Aimee Shu, (48)

Executive Vice President, Chief Medical Officer

–

Board of Directors

AC

Dr. Albert Cha (52)

Independent Chairman of the Board

139,721.00 EUR
LH

Mr. Lars Holtug (60)

Independent Director

96,169.00 EUR
LB

Ms. Lisa Bright (57)

Independent Director

92,644.00 EUR
WF

Mr. William Fairey (60)

Independent Director

73,008.00 EUR
SI

Ms. Siham Imani (47)

Independent Director

69,483.00 EUR

Frequently asked questions about Ascendis Pharma A/S

The business model of Ascendis Pharma A/S revolves around the development and commercialization of innovative therapies to address unmet medical needs. The company focuses on utilizing its proprietary TransCon technology platform to create prodrug versions of existing drugs that aim to improve their efficacy and therapeutic profile. Ascendis Pharma aims to target rare and serious conditions, particularly in endocrinology and orphan diseases. By combining its deep expertise in medical research and development with strategic partnerships and collaborations, Ascendis Pharma is dedicated to bringing transformative treatment options to patients worldwide.

Ascendis Pharma A/S is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Ascendis Pharma A/S in the market include other pharmaceutical companies such as Novo Nordisk A/S, Amgen Inc., and Eli Lilly and Company. These companies operate in the same healthcare sector and often develop and market similar medical products and treatments. Ascendis Pharma A/S faces competition from these companies in terms of research and development, innovation, and market presence. However, Ascendis Pharma A/S has established itself as a reputable player in the industry through its unique products and differentiated approach in addressing unmet medical needs.

Ascendis Pharma A/S is a reputable biopharmaceutical company headquartered in Denmark. Established in 2006, Ascendis Pharma is dedicated to developing innovative therapies for rare endocrine diseases. The company focuses on utilizing its proprietary TransCon technology platform, which enables the creation of long-acting therapies, to improve patient outcomes. Ascendis Pharma has a strong portfolio of product candidates, including TransCon hGH for growth hormone deficiency and TransCon PTH for hypoparathyroidism. With a commitment to revolutionizing treatment options, Ascendis Pharma continues to make significant strides in the field of endocrinology, enhancing the lives of patients worldwide.

Ascendis Pharma A/S has achieved several significant milestones. The company successfully developed and obtained regulatory approval for their innovative TransCon technology platform. This platform enables the production of long-acting prodrug therapies that offer improved treatment options for patients. Ascendis Pharma A/S also advanced its pipeline of therapeutic candidates, including its lead product, TransCon hGH, for the treatment of growth hormone deficiency. Additionally, the company has formed strategic collaborations with major pharmaceutical companies, further validating their innovative approach. These milestones demonstrate Ascendis Pharma A/S's commitment to advancing medical science and improving patient outcomes.

Ascendis Pharma A/S is primarily present in the United States and Europe, including countries such as Denmark, Germany, and Switzerland.

Ascendis Pharma A/S represents values of innovation, patient focus, and scientific excellence. The company is dedicated to transforming the lives of patients with rare diseases through its cutting-edge technologies and research. Ascendis Pharma takes a patient-centric approach by developing targeted therapies that address unmet medical needs. With a steadfast commitment to scientific rigor, the company aims to advance the understanding and treatment of rare diseases. Ascendis Pharma's corporate philosophy encompasses a culture of collaboration, integrity, and a drive for continuous improvement. By prioritizing the well-being of patients and staying at the forefront of scientific advancements, Ascendis Pharma A/S strives to make a positive impact in the healthcare industry.

Analysts currently set an average price target of 240.02 EUR for the Ascendis Pharma A/S stock (median: 225.13 EUR), implying +10.0 % versus the latest price. The consensus is based on 24 analyst ratings.

Ascendis Pharma A/S Analyst Price Targets 2026

24 analysts currently rate the Ascendis Pharma A/S stock: 23 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Ascendis Pharma A/S to generate revenue of 1.57 B EUR and earnings per share of 10.01 EUR.

Ascendis Pharma A/S Analyst Price Targets 2026

The Ascendis Pharma A/S share (ASND) is listed on 3 stock exchanges, including: NASDAQ (ASND), Frankfurt (A71.F), München (A71.MU).

Ascendis Pharma A/S is a biopharmaceutical company that focuses on developing innovative therapies for rare diseases. The company's business model is based on utilizing its proprietary TransCon technology platform, which consists of a combination of prodrug and carrier systems to achieve an extended drug profile. The TransCon system allows Ascendis Pharma's products to have a long half-life and controlled release, resulting in increased effectiveness and a better safety profile. The company operates in three main areas: 1. Endocrinology Ascendis Pharma focuses on developing therapies for rare endocrine diseases. The company has a pipeline of several products in various stages of clinical development targeting growth hormone deficiency, hypoparathyroidism, and hypophysitis. The leading product in Ascendis Pharma's endocrinology pipeline is TransCon HGH, a weekly administered growth hormone for individuals with growth hormone deficiency. The product is currently in Phase III of clinical development. 2. Oncology In oncology, Ascendis Pharma focuses on developing therapies for cancer treatment. The company has a pipeline of products in various stages of clinical development targeting solid tumors and hematologic malignancies. The leading product in Ascendis Pharma's oncology pipeline is TransCon PTH, a novel therapy for patients with bone metastasis from breast cancer. The product is currently in Phase I of clinical development. 3. Immunology In the immunology category, Ascendis Pharma focuses on developing therapies for rare immune-related diseases. The pipeline includes products in various stages of clinical development, including primary immunodeficiencies, autoimmune diseases, allergies, and inflammatory diseases. The leading product in Ascendis Pharma's immunology pipeline is TransCon CNP, a novel therapy for patients with vasculitis, an inflammatory disease that affects blood vessels. The product is currently in Phase I of clinical development. Ascendis Pharma has a strong pipeline and is well-positioned to benefit from its TransCon technology platform and grow as a leading provider of innovative therapies for rare diseases. Continuous development of new products is expected to ensure long-term growth within the company.

The expected revenue of Ascendis Pharma A/S is 1.57 B EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Ascendis Pharma A/S is 614.64 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Ascendis Pharma A/S is currently 21.79. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Ascendis Pharma A/S stock.

The price-to-sales ratio (P/S) of Ascendis Pharma A/S is currently 8.51. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Ascendis Pharma A/S stock.

The Eulerpool Quality Score for Ascendis Pharma A/S is 4/10.

The ISIN of Ascendis Pharma A/S is US04351P1012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Ascendis Pharma A/S is A14M6X. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Ascendis Pharma A/S is ASND. The ticker symbol is used to trade Ascendis Pharma A/S shares on the stock exchange.

Ascendis Pharma A/S paid dividends every year for the past 0 years.

Ascendis Pharma A/S is assigned to the 'Health' sector.

The dividends of Ascendis Pharma A/S are distributed in EUR.

All fundamentals and in-depth analysis of Ascendis Pharma A/S

Our stock analysis for Ascendis Pharma A/S stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ascendis Pharma A/S. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Ascendis Pharma A/S Stock
Ascendis Pharma A/S Revenue→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S Net Income→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S P/E→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S P/S→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S EBIT→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S Dividend→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S Directors Dealings→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S Stocks→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S Market capitalization→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S Debt→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S Liabilities→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S Equity→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S AAQS→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S Employees→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S ROE→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S ROA→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S ROCE→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S News→
Ascendis Pharma A/S Stock
Ascendis Pharma A/S Analyst Price Targets→

Health Stocks

Ascentage Pharma Group InternationalAscelia PharmaAscentage Pharma Group InternationalAsahi Intecc CoAscletis PharmaAs OneAscom HoldingARYx TherapeuticsAsia Vets HoldingsArypsaAsiaMedicArvinasAll Stocks A–Z →